期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

特异性siRNA抑制HPV16 E7基因表达的实验研究 被引量：2

Specific siRNA inhibits HPV16 E7 gene expression: an experimental study
原文传递
导出
摘要 目的筛选针对HPV16 E7基因有效的siRNA,探讨其对HaCaT-E7细胞中HPV16 E7 mRNA及细胞表面HLA-Ⅰ类分子表达的影响。方法采用化学法合成3条HPV16 E7特异性siRNA,应用转染试剂Lipofectamine2000将其转染入HaCaT-E7细胞,采用实时荧光定量PCR(RT-PCR)检测HPV16 E7 mRNA的表达,采用流式细胞术(FCM)检测细胞表面HLA-Ⅰ类分子的表达。结果3条siRNA均能有效抑制HaCaT-E7细胞中HPV16 E7的转录表达,以siR-NA2作用效果最明显,抑制率达75%,细胞膜表面HLA-Ⅰ类分子的表达明显上调,平均荧光强度(MFI)为130.18±1.07,高于空转染对照组(100.32±3.01)和非特异性siRNA对照组(100.82±2.87)。结论化学合成的HPV16 E7特异性siRNA能有效抑制HaCaT-E7细胞中E7 mRNA的表达,同时使细胞表面HLA-Ⅰ类分子表达上调。 Objective To screen an effective HPV16 E7 specific siRNA and investigate its effect on expression of HPV16 E7 mRNA and cell surface HLA class I antigen in HaCaT-E7 cells.Methods Three HPV16 E7 specific siRNAs were chemically synthesized and transfected into HaCaT-E7 cells by Lipofectamine2000.Expression of HPV16 E7 mRNA was determined by real-time PCR while expression of cell surface HLA class I antigen was determined by flow cytometry（FCM）.Results All three siRNAs effectively inhibited expression of HPV16 E7 mRNA in HaCaT-E7 cells.Of the siRNAs,siRNA2 was the most effective and its inhibitory rate reached 75%.Expression of cell surface HLA class I antigen was obviously up-regulated.Post-transfected average mean fluorescence intensity（MFI） of HaCaT-E7 cell surface HLA class I antigen was 130.18±1.07,which was significantly higher than that in the mock control group（100.32±3.01） and the non-specific siRNA control group（100.82±2.87）.Conclusion HPV16 E7 specific siRNA can effectively inhibit expression of E7 mRNA in HaCaT-E7 cells and induces up-regulation of cell surface HLA class I antigen.
作者 张晓 王传新 李伟 郑桂喜 张建 阚士锋 王立水
机构地区 山东大学齐鲁医院检验科
出处 《山东大学学报（医学版）》 CAS 北大核心 2009年第11期64-67,共4页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金资助项目(30672010)
关键词 乳头状瘤病毒 人 HLA抗原 基因 RNA干扰 HACAT细胞 Papillomavirus human HLA antigens Genes RNA interference HaCaT cells
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Zanotti K M, Belinson J. Update on the diagnosis and treatment of human papillomavirus infection[J]. Cleve Clin J Med, 2002, 69(12) : 948-961.
  • 2McCree D H, Leichliter J S, Hogben M, et al. National survey by specialty of U.S. physicians' HPV screening practices[J]. Pre Med, 2003, 36(2) : 159-163.
  • 3Elbashir S M, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate [ J ]. EMBO J, 2001, 20 (23) : 6877-6888.
  • 4Jonson A L, Rogers L M, Ramakrishnan S, et al. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer[J]. Gynecol Oncol, 2008, 111(2) :356-364.
  • 5Folini M, Pennati M, Zaffaroni N. RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets[J]. Methods Mol Biol, 2009, 487 : 303-330.
  • 6Yoshinouchi M, Yamada T, Kizaki M, et al. In vitro and in vivo growth suppression of human papillomavirus 16 positive cervical cancer cells by E6 siRNA [ J ]. Mol Ther, 2003, 8 (5) :762-768.
  • 7Harborth J, Arborth J, Elbashir S M, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing[J]. Antisense Nucleic Acid Drug Dev, 2003, 13(2):83-105.
  • 8Khammanivong V, Liu X S, Liu W J, et al. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16[J]. Immanol Cell Biol, 2003, 81(1):1-7.
  • 9Wang J F, Wang C X, Wang L S, et al. Association of human papillomavims type 16 E7 and HIA class Ⅰ antigen expression in cervical premahgnant and malignant lesions [ J ]. Int J Biol Markers, 2007, 22(2) : 124-131.

同被引文献23

  • 1Zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer [J]. J Natl Cancer Inst, 2001, 93(4) :252-253.
  • 2Wiley S R, Schooley K, Smolask P J, et al. Identification and characterization of new member of the TNF family that induces apoptosis[J]. Immunity, 1995, 3 ( 6 ) : 673-682.
  • 3Cobum G A, Cullen B R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference [J]. Virol, 2002, 76 ( 18 ) : 9225-9231.
  • 4Shlomai A, Shaul Y. Inhibition of hepatitis B virus ex- pression and replication by RNA interference [J]. Hepatology, 2003, 37(4) :764-770.
  • 5Butz K, Ristriani T, Hengstermann A, et al. siRNA tar- geting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells [J]. Oncogene, 2003, 22 ( 38 ) :5938-5945.
  • 6Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA-interference [J]. Oncogene, 2002, 21 (39) :6041-6048.
  • 7Oh J M, Kim S H, Lee Y I, et al. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-de- pendent pathways in cervical cancer cells [J]. Carcinogenesis, 2009, 30( 1 ) : 141-149.
  • 8Chang J T, Kuo T F, Chen Y J, et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers[J]. Cancer Gene Therapy, 2010, 17(12) :827-836.
  • 9Lea J S, Sunaga N, Sato M, et al. Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells [J]. Reprod Sci, 2007, 14 ( 1 ) :20-28.
  • 10Putral L N, Bywater M J, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin [J]. Mol Pharmacol, 2005, 68(5) :1311-1319.

引证文献2

二级引证文献3

山东大学学报（医学版）
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部